Opioid-Induced Constipation Market

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Opioid-Induced Constipation Market contains market size and forecasts of Opioid-Induced Constipation in global, including the following market information:

• Global Opioid-Induced Constipation Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Opioid-Induced Constipation Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Opioid-Induced Constipation companies in 2021 (%)

The global Opioid-Induced Constipation market was valued at 2604.3 million in 2021 and is projected to reach US$ 3520.9 million by 2028, at a CAGR of 4.4% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Methylnaltrexone Bromide Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Opioid-Induced Constipation include Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm and Nektar Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Opioid-Induced Constipation manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Opioid-Induced Constipation Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Opioid-Induced Constipation Market Segment Percentages, by Type, 2021 (%)

• Methylnaltrexone Bromide
• Lubiprostone
• Naloxegol
• Others

Global Opioid-Induced Constipation Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Opioid-Induced Constipation Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Pharmacy
• Other

Global Opioid-Induced Constipation Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Opioid-Induced Constipation Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Opioid-Induced Constipation revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Opioid-Induced Constipation revenues share in global market, 2021 (%)
• Key companies Opioid-Induced Constipation sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Opioid-Induced Constipation sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Takeda Pharmaceuticals
• Bayer
• Sanofi
• Mallinckrodt
• Salix (Bausch Health)
• AstraZeneca
• Progenics Pharmaceuticals
• Purdue Pharm
• Nektar Therapeutics
• Daiichi Sankyo
• Prestige
• GSK
• Shionogi